Analyst Ratings For Xenon Pharmaceuticals (NASDAQ:XENE) (NASDAQ:XENE)
Today, Jefferies Group raised its price target on Xenon Pharmaceuticals (NASDAQ:XENE) (NASDAQ:XENE) to per share.
Some recent analyst ratings include
- 6/27/2017-Canaccord Genuity Reiterated Rating of Buy.
- 12/22/2016-Bloom Burton initiated coverage with a Buy rating.
- 9/26/2016-Guggenheim initiated coverage with a Buy rating.
Recent Insider Trading Activity For Xenon Pharmaceuticals (NASDAQ:XENE) (NASDAQ:XENE)
Xenon Pharmaceuticals (NASDAQ:XENE) (NASDAQ:XENE) has insider ownership of 9.40% and institutional ownership of 50.87%.
- On 11/15/2017 Mohammad Azab, Director, bought 15,000 with an average share price of $2.22 per share and the total transaction amounting to $33,300.00.
- On 9/22/2017 Mohammad Azab, Director, bought 10,000 with an average share price of $2.95 per share and the total transaction amounting to $29,500.00.
- On 8/18/2017 Mohammad Azab, Director, bought 6,335 with an average share price of $2.90 per share and the total transaction amounting to $18,371.50.
- On 8/18/2017 Raymond Winquist, Insider, bought 1,000 with an average share price of $3.00 per share and the total transaction amounting to $3,000.00.
- On 8/15/2017 Bvf Partners L P/Il, Major Shareholder, bought 18,858 with an average share price of $2.41 per share and the total transaction amounting to $45,447.78.
- On 8/15/2017 James R Empfield, SVP, bought 10,000 with an average share price of $2.48 per share and the total transaction amounting to $24,800.00.
- On 8/15/2017 Value Fund L P Biotechnology, Insider, bought 60,202 with an average share price of $2.61 per share and the total transaction amounting to $157,127.22.
Recent Trading Activity for Xenon Pharmaceuticals (NASDAQ:XENE) (NASDAQ:XENE)
Shares of Xenon Pharmaceuticals (NASDAQ:XENE) closed the previous trading session at 4.90 +0.00 0.00% with 4595 shares trading hands.
